Cytokinetics Inc reports results for the quarter ended December 31 - Earnings Summary

• Cytokinetics Inc CYTK.OQ reported a quarterly adjusted loss of $1.26​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.38. The mean expectation of twenty one analysts for the quarter was for a loss of $1.19 per share. Wall Street expected results to range from $-1.52 to -30 cents per share.

• Revenue rose 912.4% to $16.93 million from a year ago; analysts expected $1.74 million.

• Cytokinetics Inc's reported EPS for the quarter was a loss of $1.26​.

• The company reported a quarterly loss of $150.02 million.

• Cytokinetics Inc shares had fallen by 0.4% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 4.7% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Cytokinetics Inc is $78.00

This summary was machine generated from LSEG data February 27 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)